CN1033071A - 特异性抗hiv抗原的单克隆抗体 - Google Patents
特异性抗hiv抗原的单克隆抗体 Download PDFInfo
- Publication number
- CN1033071A CN1033071A CN88106729A CN88106729A CN1033071A CN 1033071 A CN1033071 A CN 1033071A CN 88106729 A CN88106729 A CN 88106729A CN 88106729 A CN88106729 A CN 88106729A CN 1033071 A CN1033071 A CN 1033071A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- hiv
- antigen
- clone
- cag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000890 antigenic effect Effects 0.000 title claims description 7
- 230000036436 anti-hiv Effects 0.000 title description 7
- 239000000427 antigen Substances 0.000 claims abstract description 34
- 102000036639 antigens Human genes 0.000 claims abstract description 34
- 108091007433 antigens Proteins 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims abstract description 30
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 6
- 230000002163 immunogen Effects 0.000 claims abstract description 4
- 210000004754 hybrid cell Anatomy 0.000 claims abstract description 3
- 238000001802 infusion Methods 0.000 claims abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 42
- 210000004408 hybridoma Anatomy 0.000 claims description 11
- 238000005516 engineering process Methods 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 210000004988 splenocyte Anatomy 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000000354 decomposition reaction Methods 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 101710132601 Capsid protein Proteins 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 abstract description 4
- 239000007790 solid phase Substances 0.000 abstract description 4
- 108700004026 gag Genes Proteins 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 230000007910 cell fusion Effects 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 10
- 239000011162 core material Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000009413 insulation Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 2
- 102100024065 Inhibitor of growth protein 1 Human genes 0.000 description 2
- 241000985694 Polypodiopsida Species 0.000 description 2
- 101710107921 Secreted protein BARF1 Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001573884 Atlanta Species 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000220457 Crotalaria Species 0.000 description 1
- -1 D-mannopyranose glycosides Chemical class 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710194518 T4 protein Proteins 0.000 description 1
- 241000710914 Totivirus Species 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
提供了产生能与HIV核心抗原P55即gag基
因编码之前体蛋白、核心蛋白P24及部分分解产物
P39和P33结合的单克隆抗体的杂交细胞系。本发
明的单克隆抗体并不与P18核心蛋白或任何HIV
被膜抗原结合。本发明的细胞系是经特殊的免疫程
序建立的，其中使用一组选择的免疫原经一系列多重
输注免疫BALB/C小鼠，并用一常规使用的骨髓
瘤细胞系与收获的小鼠脾细胞融合。
该单克隆抗体被鉴定为KC-57抗体。其特别
适用于固相免疫检测法中，其中测定的是与病人血清
或血浆样品中HIV抗原结合的单克隆抗体。
Description
本发明涉及以杂交瘤技术生产的单克隆抗体，特别是涉及产生一种独特之单克隆抗体的细胞系，所说的单克隆抗体识别一组自不同地区分离的人免疫缺陷病毒（HIV）gag编码蛋白的抗原决定基。
已经认识到，目前大多称为人免疫缺陷病毒（“HIV”）的Ⅲ型人T细胞白血病病毒（HTLVⅢ）是人类免疫缺陷综合症（即爱滋病，ADIS）的致病因子。鉴于爱滋病在美国和其它一些国家造成一定比例的流行这一慢性感染特征，而对其作了广泛的研究并努力开发了检测人外周血中爱滋病病毒抗原及相应抗体的可靠而稳定的免疫诊断方法。在实际检测中，也已反过来将单克隆抗体用于发展这类免疫检测法。
HIV属于还原病毒类。还原病毒携带一正链RNA并在其核心中有一特异的逆向转录酶，其被用于将病毒RNA转化为DNA。与该过程相反的典型细胞转录过程则是将DNA转化为RNA。
已知HIV结合于T4淋巴细胞上，因为T4淋巴细胞表面上的T4蛋白质可作为HIV的受体或结合位点（Dalgleish AG等，Nature 321∶763-767（1985））。HIV还能结合并攻击其他细胞，如单核细胞、组织巨噬细胞和脑、脊髓及外周神经系统中的细胞。HIV的生活史要求病毒通过性活动或输血等途径进入宿主病人的体内，然后结合于单核细胞或淋巴细胞的受体上。病毒穿透细胞并脱去其被膜或蛋白衣壳，以使其病毒RNA核心暴露。逆转录酶使病毒RNA核心转化为DNA，进而整合到宿主细胞基因组中。在其中大量产生新的病毒颗粒，直至宿主细胞膜被破坏，以向人血循环中释放出新的病毒颗粒。
HIV系由形成封闭膜或被膜的蛋白质及包被病毒RNA抗原的核心组成。膜上和核心材料中有被表达的抗原;核心具有大部分组成病毒的蛋白质。虽然广泛使用并在理论上了解了生成单克隆抗体的常规技术，但也充分认识到了生产特异性抗体的尝试中所遇到的不少复杂情况和变化。涉及开发和生产特异性单克隆抗体的每项研究工作均会遇到各自不同的障碍而难于取得成功。任何一个特定课题能否取得成功，在很大程度上与所用抗原的性质以及用于细胞融合和分离适宜杂交瘤细胞的技术有关。对于生产分泌抗HIV特异性单克隆抗体的细胞系来说，这些障碍特别明显。HIV系由具有无数抗原决定基的被膜及表达无数抗原位点的核心蛋白所组成，由此便可很容易地了解到，骨髓瘤细胞与被免疫小鼠的脾细胞的寻常融合将产生多达用天文数字计数的杂交瘤细胞，且此后筛选特异性抗体的工作将更为繁复。
Ferns等人（J.Gen.Virol.，68∶1543-1551（1987-Great Britain））研究了识别HIV分离物之病毒蛋白的单克隆抗体。制得了抗HIV之gag蛋白的单克隆抗体。用Western吸印法鉴定了一组单克隆抗体，证实由这些单克隆抗体识别的HIVgag蛋白是分子量为55，000道尔顿（p55）、24，000道尔顿（p24）、18，000道尔顿（p18）的蛋白质，其均为核心抗原。
在Serki等人（Proc.Natl.Acad.Sci.，80∶3618-3622（1983））的研究中，已测定了HIV整个基因组的核苷酸顺序。这一研究表明，HIV被膜基因表达不同的糖基化蛋白，且核心蛋白不是糖基化的蛋白。Ferns等人（上述文献）的研究则表明，HIV被膜基因的糖基化蛋白被鉴定为分子量为160，000道尔顿的gp160、分子量为120，000道尔顿的gp120和分子量为41，000道尔顿的gp41。
这期间利用单克隆抗体检测人体是否患有爱滋病或是否与能被鉴定的病毒有过免疫学上的接触，但这些商业上可行的诊断试验尚未完全获得成功。因为在疾病表现出症状之前，需要进行这期间的保温处理，而使得对该病的诊断变得极为复杂。鉴于该病的高度感染性质以及就目前的科学水平尚不能治疗该疾病这一事实。也增加了研究活病毒及其对人类免疫系统之有害影响以发展成功的诊断试验的困难。
为此，本发明提供了一种产生能与病毒核心中选择的主要蛋白结合的新的单克隆抗体的杂交瘤或杂交细胞系。该单克隆抗体可稳定而可靠地识别某些HIV核心抗原的共同抗原决定基，故可将所说的抗体用于免疫检测法中，以高度准确地追踪人生理性血清样品中的HIV病毒抗原。该单克隆抗体不与HIV被膜抗原结合。
另外，本发明描述了以杂交瘤技术制得的细胞系，该细胞系可产生与HIV核心抗原p55（其为gag基因编码的前体蛋白）、核心蛋白p24及部分分解产物p39和p33结合的单克隆抗体。本发明的单克隆抗体不结合p18核心蛋白或任何HIV被膜抗原。单克隆抗体识别本文鉴定为“KC-57”抗原的p55、p24、p39和p33抗原上的共同抗原决定基。
本发明的细胞系是用独特的免疫程序建立的，其中使用一组选择的免疫原，经一系列多点输注免疫BALB/C小鼠并以常用的骨髓瘤细胞系与收获的小鼠脾细胞进行融合。
寄存声明
产生本发明之KC-57单克隆抗体的细胞系已于1987年11月6日提交本专利申请的同时寄存于美国典型培养物保藏中心（Rockville，Maryl and 20852）。该细胞系的寄存登记号为A.T.C.C.N.HB9585。
材料和方法
病毒分离物
由淋巴腺病毒（LAV）感染的细胞系中制备用于免疫小鼠的抗原。以分子排阻层析法由培养上清中分离全病毒。并用Triton X-100溶解LAV，然后过小扁豆植物凝血素亲合柱吸附之，以由培养上清中制备病毒提取物。经Western印迹分析显示由甲基-α，D-吡喃甘露糖苷洗脱的抗原主要是病毒被膜蛋白（gp160/120），另外存在某些核心抗原（p55、p24）。
杂交瘤细胞系的生产
将分离的LAV感染的细胞系与完全弗氏佐剂乳化后用于腹腔内免疫雄性BALB/C小鼠。然后再给小鼠腹腔内注射三次纯化的病毒（在不完全弗氏佐剂的乳悬液中），每次间隔一周。经这些注射后使小鼠每隔一周接受一次gp160/120病毒提取物免疫，共三次。第三次注射gp160/120后三天，切除一只小鼠的脾脏并制备脾细胞悬液。然后在使脾细胞在聚乙二醇1500存在下与骨髓瘤细胞融合。将融合的细胞铺敷于96小井组织培养板上，并用HAT（次黄嘌呤-氨基蝶呤-胸苷）培养基选择抗体生成杂交瘤细胞（Nature 256∶495-497，1975）。
细胞群落的筛选
用俘获ELISA法鉴定产生抗HIV核心抗原之抗体的细胞群落。将识别HIV核心抗原的人抗体吸附于96小井聚苯乙烯检测板上。用牛血清白蛋白封闭非特异性结合位点后，将去污剂破坏的LAV与检测板一起保温。然后洗涤平板并在检测平板之小井内加入各杂交瘤细胞群落的条件培养基。保温后，洗涤平板，加入过氧化物酶连接的羊抗小鼠IgG+IgA+IgM并保温。再次洗涤各小井，并加入底物四甲基联苯胺（TMB）。用H2SO4终止反应并测定450nm处吸光率。经鉴定，含KC-57的阳性细胞群落之吸光率比阴性细胞群落的吸光率至少高3倍。克隆到软琼脂胶中以扩充阳性细胞群落，然后注入姥鲛烷（pristane）刺激的BALB/C小鼠体内，以使之产生含抗体的腹水液。
KC-57的特性
经Ouchterlony免疫双扩散法测知KC-57的免疫球蛋白亚类为IgGl。完成Western吸印实验以测定被KC-57识别的抗原的分子量。用LAV感染之细胞的溶胞产物作为这一分析的抗原来源。抗原阴性对照是未感染T细胞的溶胞产物。证明对照制剂与KC-57无反应活性。使用的内部分子量标志物有血纤维蛋白原（340，000）、纤维结合素（440，000）、肌球蛋白（200，000）、β-半乳糖苷酶（116，000）、磷酸化酶B（92，500）、牛白蛋白（66，000）、卵白蛋白（43，000）、碳酸酐酶（30，000）、胰蛋白酶抑制剂（20，100）和α-乳清蛋白（14，000）。将硝化纤维素滤膜条与KC-57一起保温后，用125I标记的羊抗小鼠抗体检测被单克隆抗体识别的HIV抗原。KC-57可识别HIV相关核心抗原p55和p24，以及可能是p55之裂解产物的p39和p31。没有检出与p18及各HIV被膜抗原的反应活性。
用EPICS流动细胞计数装置（Coulter公司，Healeah，Florida）分析KC-57识别的HIV相关抗原在细胞表面的表达。LAV感染的细胞与KC-57一起保温，然后与羊抗小鼠FITC结合物保温。结果证明KC-57与活的HIV感染的细胞表面上的抗原决定基无反应活性。
使用丙酮固定的LAV感染的细胞完成脆质HIV核心相关抗原的表达。另外，得到并以相同方式制备未感染的、HTLV-Ⅰ感染的和HTLV-Ⅱ感染的淋巴细胞。与KC-57保温后，用羊抗小鼠FITC结合物检测特异反应活性。结果证明KC-57与未感染的、HTLV-Ⅰ感染的或HTLV-Ⅱ感染的细胞无反应活性，而只与存在于固定的HIV感染的淋巴细胞胞质中的核心相关抗原产生特异性反应。
建立一使用KC-57作俘获抗体的抗原俘获酶免疫检测法（EIA）。在96小井检测平板上将纯化的KC-57制成固相并用BSA封闭。以去污剂溶解的LAV感染之淋巴细胞的培养物上清作为HIV抗原来源。保温并洗涤后，加入生物素标记的人抗HIV核心抗体，再次保温并洗涤。加入抗生蛋白链菌素（streptavidin）过氧化物酶并继续保温。末次洗涤后加入TMB并保温。加硫酸终止反应。读出450nm处的吸光率。使用这一分析方法，生长于组织培养物中的9个个别的HIV分离物均获得阳性结果。用以检测这一反应活性的抗原是去污剂溶解的培养物上清。与未感染之细胞的上清未见有反应活性。下列表3中给出了分析数据。
KC-57单克隆抗体特别适用于固相免疫检测，其中所说的单克隆抗体包被于固相表面（如微量滴定板的小井）上并在一控制的程序中与人生理体液样品反应。检测法可以是酶联免疫吸附检测法（ELISA），其中所检测的是与样品中HIV抗原结合的KC-57单克隆抗体。
表3
KC-57HIV抗原俘获ELISA
HIV分离物 分离病毒的地区 结果
LAV 法国 +
BAGAL 纽约城 +
1265 D13 亚特兰大 +
Z34 托伊尔 +
SDR 旧金山 +
2153 D16 纽约城 +
121886-1 Bethesda +
1272 D21 芝加哥 +
表3所示的结果表明，用KC-57单克隆抗体作俘获相、人抗HIV抗体作检测相的HIV抗原检测法，鉴定上列所有病毒株结果均呈阳性反应。
表4
KC-57单克隆抗体的特异性
感染因子 检测数 阳性数
EBV 2 0
HTLV Ⅰ 2 0
HTLV Ⅱ 2 0
HSV Ⅰ 2 0
HSV Ⅱ 2 0
CMV 2 0
Chlamydia 2 0
上表数荼砻髁说苯猩鲜龅腍IV抗原检测时KC-57抗体与被测的其他感染因子均未见有阳性反应活性。
上表证明KC-57单克隆抗体在所说的HIV抗原检测法中用作俘获抗体时的抗其他感染因子的反应活性。
Claims (12)
1、以杂交瘤技术建立的细胞系，其可产生识别一组有共同抗原决定基的HIV核心抗原，且基本上不识别HIV被膜抗原的KC-57单克隆抗体。
2、根据权利要求1所述的细胞系，其中所说的核心抗原包括P55、P24及其他分解的抗原。
3、根据权利要求1的细胞系，其中单克隆抗体是由小鼠脾细胞制得的。
4、根据权利要求1的细胞系，其中所说的脾细胞是经一系列不同的免疫原免疫后制备的。
5、根据权利要求4的细胞系，其中所说的免疫原包括依次输注的分离的LAV感染的细胞系、纯化的HIV病毒及gp160/120。
6、根据权利要求3的细胞系，其中所说的脾细胞是与小鼠骨髓瘤细胞融合的。
7、寄存于美国典型培养物保藏中心（Rockville，Maryland）且登记号为A.T.C.C.N.HB9585的杂交细胞系样品。
8、由寄存于美国典型培养物保藏中心（Rockville，Maryland）且登记号为A.T.C.C.N.HB9585的杂交瘤样品产生的单克隆抗体。
9、得自以杂交瘤技术生产之细胞系的单克隆抗体，其特征是：
A.将由多种病毒分离物制备的抗原注射到小鼠体内，收获小鼠脾细胞以与小鼠骨髓瘤细胞系融合;
B.筛选融合的细胞以分离可与包括P55、P24及某些分解的核心抗原在内的一组HIV核心抗原之KC-57抗原产生特异结合的单克隆抗体;以及
C.KC-57抗原的同型免疫球蛋白是小鼠IgG1。
10、与一组HIV核心抗原之KC-57抗原结合但基本上不与HIV被膜抗原结合的单克隆抗体。
11、根据权利要求10的单克隆抗体，其中所说的核心抗原包括P55和P24抗原。
12、根据权利要求11的单克隆抗体，其中所说的核心抗原包括P39和P33抗原。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/118,145 US4888290A (en) | 1987-11-06 | 1987-11-06 | Monoclonal antibody specific to HIV antigens |
| US118,145 | 1987-11-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1033071A true CN1033071A (zh) | 1989-05-24 |
| CN1025219C CN1025219C (zh) | 1994-06-29 |
Family
ID=22376739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN88106729A Expired - Fee Related CN1025219C (zh) | 1987-11-06 | 1988-09-15 | 制备可产生特异性抗hiv抗原的单克隆抗体的杂交瘤细胞系的方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4888290A (zh) |
| EP (1) | EP0415920B1 (zh) |
| JP (1) | JP2710972B2 (zh) |
| KR (1) | KR960016304B1 (zh) |
| CN (1) | CN1025219C (zh) |
| AU (1) | AU612686B2 (zh) |
| CA (1) | CA1339350C (zh) |
| DE (1) | DE3854502T2 (zh) |
| ES (1) | ES2016427A6 (zh) |
| IE (1) | IE61241B1 (zh) |
| IL (1) | IL87535A (zh) |
| WO (1) | WO1989004376A1 (zh) |
| ZA (1) | ZA884651B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387617C (zh) * | 1999-03-04 | 2008-05-14 | 比奥诺尔免疫有限公司 | Hiv肽,抗原,疫苗组合物,检测hiv所诱导的抗体的免疫测定试剂盒及方法 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5104790A (en) * | 1987-06-29 | 1992-04-14 | Genetic Systems Corporation | Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use |
| US4886742A (en) * | 1987-06-15 | 1989-12-12 | Coulter Corporation | Enzyme immunoassay for detecting HIV antigens in human sera |
| ZA903492B (en) * | 1989-05-15 | 1991-02-27 | Akzo Nv | T-lymphotropic retrovirus monoclonal antibodies |
| US5210181A (en) * | 1989-05-15 | 1993-05-11 | Akzo N.V. | T-lymphotropic retrovirus peptide |
| DE69112059T2 (de) * | 1990-06-01 | 1996-02-29 | Lepetit Spa | Monoklonale antikörper gegen gag-protein-vorläufer-p55 von hiv-virus. |
| US5164293A (en) * | 1990-09-25 | 1992-11-17 | Coulter Corporation | Monoclonal antibody for detecting HTLV-I, HTLV-II and STLV-I viruses |
| EP0519866A1 (en) * | 1991-06-18 | 1992-12-23 | Ciba-Geigy Ag | Novel anti-HIV antibodies |
| US5451525A (en) * | 1992-02-14 | 1995-09-19 | Coulter Corporation | Method and materials for determining particle count in a flow cytometer |
| US6319665B1 (en) | 1994-06-07 | 2001-11-20 | Inverness Medical Technology, Inc. | Home test kit and method with telephone verification of results |
| AU5082698A (en) * | 1996-10-23 | 1998-05-15 | Oravax, Inc | Heat inactivation of viruses in antibody preparations |
| US5891994A (en) * | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| US5902722A (en) * | 1997-12-05 | 1999-05-11 | The Perkin-Elmer Corporation | Method of detecting organisms in a sample |
| US5915307A (en) * | 1998-01-29 | 1999-06-29 | Suncast Corporation | Sports shelf |
| US6399067B1 (en) * | 2000-04-28 | 2002-06-04 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| US6818392B2 (en) * | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
| EP1851247A2 (en) | 2005-02-15 | 2007-11-07 | Thymon L.L.C. | Methods and compositions for impairing multiplication of hiv-1 |
| US20080108054A1 (en) * | 2006-08-28 | 2008-05-08 | Jayasri Basu | Detecting early HIV infection in genital tract cells and secretions |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| CN110669133A (zh) * | 2019-10-18 | 2020-01-10 | 普健生物（武汉）科技有限公司 | 利用尾静脉注射进行基因免疫开发小鼠单克隆抗体的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8501473D0 (en) * | 1985-01-21 | 1985-02-20 | Pasteur Institut | Cloned dna sequences |
-
1987
- 1987-11-06 US US07/118,145 patent/US4888290A/en not_active Expired - Lifetime
-
1988
- 1988-06-10 JP JP63506392A patent/JP2710972B2/ja not_active Expired - Fee Related
- 1988-06-10 DE DE3854502T patent/DE3854502T2/de not_active Expired - Lifetime
- 1988-06-10 WO PCT/US1988/001997 patent/WO1989004376A1/en active IP Right Grant
- 1988-06-10 EP EP88906574A patent/EP0415920B1/en not_active Expired - Lifetime
- 1988-06-10 AU AU21337/88A patent/AU612686B2/en not_active Ceased
- 1988-06-14 IE IE179988A patent/IE61241B1/en not_active IP Right Cessation
- 1988-06-21 CA CA000570000A patent/CA1339350C/en not_active Expired - Fee Related
- 1988-06-29 ZA ZA884651A patent/ZA884651B/xx unknown
- 1988-08-23 IL IL87535A patent/IL87535A/xx not_active IP Right Cessation
- 1988-09-15 CN CN88106729A patent/CN1025219C/zh not_active Expired - Fee Related
- 1988-11-04 ES ES8803362A patent/ES2016427A6/es not_active Expired - Fee Related
-
1989
- 1989-07-05 KR KR1019890701259A patent/KR960016304B1/ko not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387617C (zh) * | 1999-03-04 | 2008-05-14 | 比奥诺尔免疫有限公司 | Hiv肽,抗原,疫苗组合物,检测hiv所诱导的抗体的免疫测定试剂盒及方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US4888290A (en) | 1989-12-19 |
| ZA884651B (en) | 1990-03-28 |
| KR890701771A (ko) | 1989-12-21 |
| AU612686B2 (en) | 1991-07-18 |
| CN1025219C (zh) | 1994-06-29 |
| KR960016304B1 (ko) | 1996-12-09 |
| IE881799L (en) | 1989-05-06 |
| IL87535A (en) | 1993-01-14 |
| CA1339350C (en) | 1997-08-26 |
| IE61241B1 (en) | 1994-10-19 |
| AU2133788A (en) | 1989-06-01 |
| WO1989004376A1 (en) | 1989-05-18 |
| EP0415920A4 (en) | 1993-03-17 |
| JP2710972B2 (ja) | 1998-02-10 |
| DE3854502T2 (de) | 1996-04-18 |
| EP0415920A1 (en) | 1991-03-13 |
| EP0415920B1 (en) | 1995-09-20 |
| JPH03500483A (ja) | 1991-02-07 |
| DE3854502D1 (de) | 1995-10-26 |
| ES2016427A6 (es) | 1990-11-01 |
| IL87535A0 (en) | 1989-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1025219C (zh) | 制备可产生特异性抗hiv抗原的单克隆抗体的杂交瘤细胞系的方法 | |
| DE3588251T2 (de) | DNS-Fragmente des GAG-Gens von LAV | |
| Ljunggren et al. | IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. | |
| di Marzo Veronese et al. | Monoclonal antibodies specific for p24, the major core protein of human T-cell leukemia virus type III. | |
| Matsushita et al. | Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. | |
| US5550052A (en) | Hybrid cell line formed between T4 lymphocytes and tumoral lymphoid type cells | |
| JP2002503941A (ja) | Ｈｉｖ−２に対するモノクローナル抗体及びその使用 | |
| US6531574B1 (en) | T-lymphotrophic virus | |
| RU2082417C1 (ru) | Противовирусное средство, вакцина на его основе, способ ее получения, терапевтический агент и способ обнаружения компонентов рнк-вирусов | |
| Lipka et al. | Modified Western blot assay for confirmation and differentiation of human T cell lymphotropic virus types I and II | |
| DE69110891T2 (de) | Peptide und analoge und mischungen davon zum nachweis der gegen die viren htlv-1 und htlv-ii gerichteten antikörper. | |
| EP0605433B1 (en) | Immunoassay for the simultaneous detection of hiv-1, hiv-2, htlv-i and htlv-ii antibodies | |
| Haley et al. | Influence of antibody infusion on pathogenesis of experimental feline leukemia virus infection | |
| Blomberg et al. | Immunoglobulin G antibodies binding to a synthetic peptide deduced from the nucleotide sequence of the env gene of HTLV I in patients with leukemia and rheumatoid arthritis, HLA sensitized persons and blood donors | |
| LONDOS-GAGLIARDI et al. | Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein. | |
| US20010014470A1 (en) | T-lymphotrophic virus | |
| Fox¹ et al. | Lymphoproliferative disorders in Sjögren's syndrome | |
| EP0379516A1 (en) | GLOBULIN HYPER-IMMUNE AGAINST HIV. | |
| EP0808846A2 (en) | Peptides which react with antiboby representing the prognostic marker for HIV disease progression | |
| Goudsmit et al. | Immunoglobulin subclasses of antibodies to human T-cell leukemia/lymphoma virus I-associated antigens in acquired immune deficiency syndrome and lymphadenopathy syndrome | |
| Hui-yu et al. | Antibody Against the Human Immunodeficiency Virus in Guangdong Province, China | |
| CN1045035A (zh) | 通过被动免疫治疗或预防人免疫缺陷病毒感染的药物及其制备方法 | |
| AU7540887A (en) | Small peptides which inhibit binding to t-4 receptors and act as immunogens | |
| Kieber-Emmons et al. | Immunological characteristics of the putative CD4-binding site of the HIV-1 envelope protein | |
| Insert | Bilirubin-Specific Enzyme Preparation, Assay Compositions, Analytical Elements and Methods Using Same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |